Online Educational Activity
ACR 2008: The Latest Evidence for Targeted RA Therapy
Needs Statement/Intended Audience
This activity is intended to provide rheumatologists with the latest information from ACR about targeted RA therapy.
Educational Activity Learning Objectives
Upon completion of this activity, the participants should be able to:
- Describe current and emerging therapies for RA, including both small molecule and biologic DMARDs
- Demonstrate awareness of the latest clinical trial results on the benefits and risks of new and emerging biologics
- Describe newer paradigms for RA management, including current expert thinking and clinical trial results on the value of early detection, close monitoring and aggressive treatment
- Demonstrate up-to-date knowledge of RA disease activity indices and their utility in different clinical situations
Credit Statement
The France Foundation designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Faculty
Marc D. Cohen, MD
Professor of Medicine
Chief of Rheumatology
National Jewish Medical and Research Center
Denver, Colorado
Release/Expiration Dates
This activity is eligible for CME credit from December 2008 through December 31, 2009.
Commercial Support Acknowledgment
This educational activity is supported by independent educational grants from Bristol-Myers Squibb and Roche.
Print
Email This Page
Digg
